Results & Expectations
    Retatrutide

    Retatrutide 1-Month Results

    The first month on retatrutide is about building a foundation -- adjusting to the medication, managing early side effects, and starting to see the scale move. Here is what the data shows and what patients can realistically expect.

    Published: April 3, 202613 min read

    The first month on retatrutide sets expectations for the entire treatment journey. Patients who understand that the titration phase produces modest initial results -- and that the dramatic 24% weight loss seen in Phase 2 trials (Jastreboff et al., NEJM 2023) develops over 48 weeks, not 4 -- are more likely to stay committed through the early adjustment period and ultimately achieve their goals.

    Data Context

    Weight loss figures are estimates based on Phase 2 trial data at starting doses. Individual results vary significantly. Retatrutide is investigational and not FDA-approved.

    Week-by-Week First Month

    Month 1 Timeline

    Week 1: Adjustment

    First injection at starting dose (0.5-1mg). Mild appetite reduction begins within 2-3 days. Possible nausea, typically mild. Weight loss: 1-3 pounds (mostly water and glycogen initially).

    Week 2: Settling In

    Second injection. Appetite suppression becomes more noticeable. GI side effects may peak then begin to improve. Weight loss: 1-2 additional pounds. Drug levels approaching steady state at starting dose.

    Week 3: Finding Your Rhythm

    Third injection. Body adapting to medication. Appetite consistently reduced. Side effects typically improving. Weight loss continuing at 1-2 pounds per week. Starting to establish new eating patterns.

    Week 4: First Milestone

    Fourth injection. Steady state achieved at starting dose. Dose increase may be prescribed. Total month 1 weight loss: typically 3-6% of body weight. Clothing may begin to feel slightly looser.

    What to Focus on in Month 1

    • Protein intake: Begin establishing the habit of prioritizing protein at every meal. Target 80-120 grams daily.
    • Hydration: Drink at least 64 ounces of water daily. GLP-1 medications increase dehydration risk.
    • Exercise initiation: Start with daily walking (15-30 minutes) and introduce basic resistance training 2x per week.
    • Side effect management: Eat small, frequent meals. Avoid greasy and heavy foods. Ginger tea or ginger candies can help with nausea.
    • Mindset: Focus on the process, not the scale. The dramatic results come in months 3-12, not month 1.

    When to Contact Your Provider

    While mild side effects are normal, contact your provider if you experience persistent vomiting (unable to keep liquids down), severe abdominal pain, signs of pancreatitis (radiating abdominal pain with nausea), or inability to eat or drink for more than 24 hours.

    To get started with currently available weight loss treatments, visit our treatments page.

    Medical Disclaimer

    This article is for educational purposes only. Retatrutide is not FDA-approved. Results are estimates based on Phase 2 data (Jastreboff et al., NEJM 2023). Individual results vary. Consult a healthcare provider for treatment guidance.

    Start Your Month 1 Today

    Begin losing weight now. Semaglutide from $99/mo, tirzepatide from $125/mo.

    Get Started Today

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for retatrutide?

    Peer-reviewed evidence: Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023). Trimi is preparing for launch; compounded availability depends on FDA-cleared compounding pathways. Results vary by individual; eligibility is determined by a licensed clinician.

    Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. — Jastreboff et al. Phase 2 trial, NEJM 2023
    Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. — Rosenstock et al. Phase 2 T2D trial, Lancet 2023

    Key Takeaways

    • Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023)
    • Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. (Source: Rosenstock et al. Phase 2 T2D trial, Lancet 2023)
    • Retatrutide is investigational and not FDA-approved as of publication. Trial findings reported here are from Phase 2 / Phase 3 studies in peer-reviewed sources cited below.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: October 31, 2025

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    Sarah MillerFacebook
    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    Veronica LarimoreFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2301972
    2. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet.Read StudyDOI: 10.1016/S0140-6736(23)01053-X
    3. ClinicalTrials.gov (2024). A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1) — NCT05929066. ClinicalTrials.gov.Read Study
    4. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    5. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    6. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Step-by-step retatrutide injection: 6-day half-life, once-weekly dosing, site rotation, and how to time shots for fewer side effects and better weight loss results.

    Week-by-week weight loss expectations on retatrutide. Understand the typical trajectory from first injection through 48 weeks, including acceleration phases, plateaus, and realistic weekly targets.

    Guide to semaglutide 0.5mg dose increase. Learn what to expect at the first titration step, typical side effects, weight loss results, and when to advance to 1.0mg.

    What to expect after 3 months on retatrutide: typical weight loss, body changes, metabolic improvements, and how results compare to semaglutide and tirzepatide at the same timepoint.

    Start your GLP-1 journey — from $99/mo

    Get Started